Guidant Lower after Court Setback

Lilly's attention-deficit drug gets FDA nod; Hormel cautiously optimistic on fiscal 2003; plus more of today's stocks to watch

Boston Scientific (BSX ) says a U.S. appeals court denied requests by Cook Inc. and Guidant (GDT ) for a stay of injunction in their paclitaxel-coated stent dispute with Boston Scientific. Guidant shares fell on the news while Boston Scientific traded higher. CIBC World reiterated its sector underperform rating on Guidant.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.